# Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

> **NCT05781308** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 156 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT05781308
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2025-06-02
- **Final completion:** 2026-06
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05781308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05781308, "Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05781308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*